References
- Bussel J, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. In: Michiels JJ, editor. Acquired disorders of haemostasis: pathophysiology, clinical practice and basic research. London: Bailliere Tindall; 1998. pp 391–408.
- Durand-Zaleski I, Schlegel N, Blum-Boisgard C, Uzan S, Dreyfus M, Kaplan C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: Perinatol 1996;13:423–31.
- Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002;16:69–72.
- Kanhai HHH, Porcelijn L, Engelfriet CP, Reesink HW, Panzer S, Ulm B, Goldman M, Bonacossa I, Richard L, David M, et al Management of alloimmune thrombocytopenia. Vox Sang 2007;93:370–385.
- Paidas MJ, Berkowitz RL, Lynch L, Lockwood CJ, Lapinski R, McFarland JG, Bussel JB. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995;172:475–479.
- Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, Bussel JB. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol 2007;110:249–255.
- van den Akker ES, Oepkes D, Lopriore E, Brand A, Kanhai HH. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007;114:469–473.
- Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009;7:253–257.
- Yinon Y, Spira M, Solomon O, Weisz B, Chayen B, Schiff E, Lipitz S. Antenatal non invasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrage. Am J Obstet Gynecol 2006;195:1153–1157.
- Berkowitz RL, Bussel JB, McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol 2006;195:907–913.
- Weiner CP, Wenstrom KD, Sipes SL, Williamson RA. Risk factors for cordocentesis and fetal intravascular transfusion. Am J Obstet Gynecol 1991;165:1020–1025.
- Jolly MC, Letsky EA, Fisk NM. The management of fetal alloimmune thrombocytopenia. Prenat Diagn 2002;22:96–98.
- Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang 2003;84:318–325.
- Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev 2008;22:33–52.
- Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol 2006;136:366–378.
- Bussel JB, Berkowitz RL, Lynch L, Lesser ML, Paidas MJ, Huang CL, McFarland JG. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous γ-globulin. Am J Obstet Gynecol 1996;174:1414–1423.
- Lynch L, Bussel JB, McFarland JG, Chitkara U, Berkowitz RL. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992;80:67–71.
- Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Hauge R, Øian P, Dahl LB, Pirhonen JA, et al A screening and intervention program aimed to reduced mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007;110:833–839.